We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Center Founded for Study of Molecular Medicine

By Biotechdaily staff writers
Posted on 20 May 2002
A center has been founded for the study of the genetic basis of disease, the future of modern medicine. More...
The University of Pittsburgh School of Medicine (USA) has partnered with the University of Pittsburgh Medical Center (UPMC, USA) Health System to develop this center, called the Molecular Medicine Institute (MMI).

Research within the MMI will involve studying animal models of human disease to reveal obstacles and provide solutions to impediments to gene and protein therapy. The UPMC Health System will provide many of the resources necessary to carry out this complex scientific venture, including vector development, manufacturing capabilities, a vast patient base, funding, and professional support. Programs that will be under the MMI's auspices include gene transfer and gene therapy and peptide mediated protein delivery. The institute will be housed in the Biotechnology and Bioengineering Center. Joseph Glorioso, Ph.D., a professor of biochemistry and chairman of the molecular genetics and biochemistry department at the Pittsburgh School of Medicine, will serve as director of the MMI.

"The MMI is the culmination of many years of research into the development of gene and protein therapeutics at the University of Pittsburgh,” said Dr. Glorioso. "Members of the institute will work closely with other institutes whose missions include diabetes, regenerative medicine, cancer, and transplantation, providing expertise in gene transfer methodologies and purified proteins for manipulation of cells and tissues.”




Related Links:
University of Pittsburgh School of Medicine

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Pre- Eclampsia Control
Acusera Pre-Eclampsia Control
Urine Analyzer
respons® UDS100
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Alzheimer’s pathology can start 15 to 20 years before symptoms, and validated tools that reach patients earlier help pave the way for earlier detection. (Image Credit: Adobe Stock)

Alzheimer’s Blood Test Becomes First FDA-Cleared Option for Adults as Young as 40

C2N Diagnostics’ PrecivityAD2 blood test was cleared by the U.S. Food and Drug Administration (FDA) on August 20, 2026, for adults as young as 40 who are experiencing signs of cognitive impairment, according... Read more

Pathology

view channel
Image: Adrenal gland tumor stained with hematoxylin and eosin (top) and CYP11B2 (bottom) (Photo courtesy of Christofer Juhlin)

Simple Immunohistochemical Size Ratio Improves Classification of Primary Aldosteronism

Primary aldosteronism is a common but underdiagnosed cause of hypertension, in which excess aldosterone promotes salt retention and raises blood pressure. Identifying the dominant source of hormone overproduction... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.